Asymmetric hydrogenation of pharmaceutically interesting substrates.
The application of asymmetric hydrogenation to the manufacture of pharmaceutical intermediates has become increasingly prevalent in the past three to five years. This review focuses on the hydrogenation substrates and their use, rather than comparing the specific catalysts employed. The literature published between 2002 and 2003 is covered, with some pertinent examples from 2001, all of which demonstrate the increasing number of applications for this technology.
Lennon
Ian C
IC
Dowpharma, Chirotech Technology Ltd a Subsidiary of the Dow Chemical Company, Unit 321, Cambridge Science Park, Milton Road, Cambridge, CB4 0WG, UK. ilennon@dow.com
Moran
Paul H
PH
D000475:Alkenes / Q000138:chemical synthesis; D000596:Amino Acids / Q000138:chemical synthesis; D002626:Chemistry, Pharmaceutical; D006571:Heterocyclic Compounds / Q000737:chemistry; D006865:Hydrogenation; D007097:Imines / Q000138:chemical synthesis; D007659:Ketones / Q000138:chemical synthesis; D004364:Pharmaceutical Preparations / Q000138:chemical synthesis*; D013379:Substrate Specificity; D006113:United Kingdom
D000475:Alkenes; D000596:Amino Acids; D006571:Heterocyclic Compounds; D007097:Imines; D007659:Ketones; D004364:Pharmaceutical Preparations